# A Study of Mosliciguat in PH-ILD

Study · id `cardio:ct-nct06635850` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06635850](<https://clinicaltrials.gov/study/NCT06635850>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06635850

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 135 participants.

## Technical summary

Registry record NCT06635850. Randomized; quadruple masking; primary purpose treatment. Start 2024-10-29 (actual); primary completion 2026-05-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 135 participants (enrolled count; ClinicalTrials.gov record NCT06635850, source copy `cardio:ctgov-nct06635850-2026-09-10`, retrieved 2026-10-31)
- Started: 2024-10-29 (actual) (ClinicalTrials.gov record NCT06635850, source copy `cardio:ctgov-nct06635850-2026-09-10`, retrieved 2026-10-31)
- Primary completion: 2026-05-26 (actual) (ClinicalTrials.gov record NCT06635850, source copy `cardio:ctgov-nct06635850-2026-09-10`, retrieved 2026-10-31)
- Completion: 2028-01 (anticipated) (ClinicalTrials.gov record NCT06635850, source copy `cardio:ctgov-nct06635850-2026-09-10`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Canada; Czechia; France; Germany; Italy; Japan; Latvia; Mexico; Netherlands; New Zealand; Poland; South Korea; Spain; Türkiye; United Kingdom (ClinicalTrials.gov record NCT06635850, source copy `cardio:ctgov-nct06635850-2026-09-10`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06635850-2026-09-10`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of Mosliciguat in PH-ILD
- Acronym: PHocus
- Condition: Pulmonary Hypertension
- Condition: Interstitial Lung Disease
- Condition: Lung Diseases
- Condition: Vascular Diseases
- Condition: Cardiovascular Diseases
- Condition: Fibrosis
- Intervention (Drug): Mosliciguat
- Intervention (Device): Dry Powder Inhaler
- Intervention (Drug): Placebo
- Lead sponsor: Pulmovant, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: 602004adeb98a1fe007530e51413d42ca61f08535484f3614e3d927f0cd15c3d
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
